SCHEMBL14691916

SCHEMBL14691916

Cn1c(=O)[nH]c(=O)c2cccc(Cl)c21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 3/20 0.47
▸ HDAC8 Q9BY41 2/20 0.47
▸ HDAC3 O15379 1/20 0.47
▸ HDAC4 P56524 1/20 0.47
▸ HDAC1 Q13547 1/20 0.47
▸ HDAC7 Q8WUI4 1/20 0.47
▸ HDAC2 Q92769 1/20 0.47
▸ HDAC11 Q96DB2 1/20 0.47
▸ HDAC9 Q9UKV0 1/20 0.47
▸ HDAC5 Q9UQL6 1/20 0.47
▸ ADORA3 P0DMS8 1/20 0.46
▸ ADORA2A P29274 1/20 0.46
▸ ADORA2B P29275 1/20 0.46
▸ ADORA1 P30542 1/20 0.46
▸ PARP1 P09874 2/20 0.45
▸ PSMB8 P28062 1/20 0.44
▸ GUSB P08236 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29785322 0.79 ADORA3 (0.46) ADORA3ADORA2AADORA2BADORA1PARP1
SCHEMBL6395773 0.74 ADORA2B (0.41) ADORA3ADORA2AADORA2BADORA1KMT2A
SCHEMBL14290183 0.72 HDAC1 (0.47) HDAC6HDAC8HDAC1PARP1POLB
SCHEMBL5033267 0.71 GPR3 (0.52) ADORA3ADORA2AADORA2BADORA1PARP1
SCHEMBL25276159 0.70 TNKS (0.37) HDAC6HDAC8HDAC1KDM4EALDH1A1
SCHEMBL31204111 0.70 TNKS (0.37) HDAC6HDAC8HDAC1KDM4EALDH1A1
SCHEMBL8488837 0.70 HDAC6 (0.53) HDAC6HDAC8HDAC3HDAC4HDAC1
Benzene SCHEMBL28335868 0.69 ADORA3 (0.50) ADORA3ADORA2AADORA2BADORA1PARP1
SCHEMBL11503490 0.69 NQO2 (0.64) KDM4EALDH1A1HPGDKMT2AGRM4
SCHEMBL9523208 0.69 FEN1 (0.66) ADORA3ADORA2AADORA2BADORA1PSMB8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8916573-B2 Quinazoline-2,4-dione derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2014-12-23 — — US disclosed
US-20140171425-A1 QUINAZOLINE-2,4-DIONE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2014-06-19 — — US disclosed
EP-2742042-A1 QUINAZOLINE-2,4-DIONE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2014-06-18 — — EP disclosed
WO-2013021363-A1 QUINAZOLINE-2,4-DIONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-02-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171425-A1 QUINAZOLINE-2,4-DIONE DERIVATIVES NQO2, H1-3, H1-0 HDAC6 277/4885HDAC8 889/4885HDAC3 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback